Filing Flows › Comparisons › PREM vs VVOS
Premier Air Charter Holdings vs Vivos Therapeutics: PREM and VVOS compared
Premier Air Charter Holdings is the larger company: $5.8M of revenue in its latest quarter (Q2 2026) against $5.2M for Vivos Therapeutics (Q2 2026). Vivos Therapeutics is growing faster (+35% against -22% a year earlier). Premier Air Charter Holdings is more profitable, with an operating margin of -15.7% against -93.6%.
Where the money goes: PREM and VVOS
Premier Air Charter Holdings (PREM) · Q2 2026
Premier Air Charter Holdings, Q2 2026: revenue $5.8M (-22% year over year), operating margin -15.7%, net loss $1.3M, operating cash flow $318K. The chart follows the revenue to costs, profit and cash.
Vivos Therapeutics (VVOS) · Q2 2026
Vivos Therapeutics, Q2 2026: revenue $5.2M (+35% year over year), operating margin -93.6%, net loss $5.5M, operating cash flow −$3.1M. The chart follows the revenue to costs, profit and cash.
| Premier Air Charter Holdings (PREM) | Vivos Therapeutics (VVOS) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $5.8M | $5.2M |
| Revenue growth, Y/Y | -22% | +35% |
| Operating margin | -15.7% | -93.6% |
| Net earnings | −$1.3M | −$5.5M |
| Net margin | -22.3% | -107.2% |
| Operating cash flow | $318K | −$3.1M |
Where the revenue comes from
Vivos Therapeutics
- Service: $3.8M (74%)
- Product: $1.4M (26%)
Questions
Which is bigger, Premier Air Charter Holdings or Vivos Therapeutics?
Premier Air Charter Holdings is the larger company: $5.8M of revenue in its latest quarter (Q2 2026) against $5.2M for Vivos Therapeutics (Q2 2026).
Is Premier Air Charter Holdings or Vivos Therapeutics growing faster?
Vivos Therapeutics is growing faster (+35% against -22% a year earlier).
Which is more profitable, Premier Air Charter Holdings or Vivos Therapeutics?
Premier Air Charter Holdings is more profitable, with an operating margin of -15.7% against -93.6%.
More: Premier Air Charter Holdings earnings · how Premier Air Charter Holdings makes money · Vivos Therapeutics earnings · how Vivos Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 14, 2026; 10-Q filed Aug 14, 2026). Fiscal quarters can end on different dates. Not investment advice.